Thieler Law Corp advises investors with losses exceeding $100,000 of the December 10, 2018 lead plaintiff deadline in a class action lawsuit filed against Trevena Inc (NASDAQ: TRVN) (“Trevena” or “the Company”). The suit is pending in the U.S. District Court for the Eastern District of Pennsylvania and investors, who purchased Trevena Inc securities between May 2, 2016 and October 8, 2018, have until December 10, 2018 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Trevena Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Trevena misled its shareholders into believing that its April 28, 2016 End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (“FDA”) for its drug candidate, Oliceridine, was far more successful than it actually was; the FDA did not agree with the proposed dosing in the Phase 3 studies, the proposed primary endpoint, and the proposed non-inferiority margin for comparing morphine to Oliceridine; and as a result, defendants’ public statements were materially false and misleading at all relevant times.

On October 9, 2018, it was disclosed that the FDA notified the Company at a meeting in 2016, that the FDA “did not agree with the proposed dosing in the Phase 3 studies,” the proposed primary endpoint, or the “proposed non-inferiority (NI) margin for comparing morphine to oliceridine.”

On this news, NASDAQ: TRVN fell more than 64% on October 9, 2018 to close at $1.07 per share.

On October 11, 2018, Trevena revealed that the FDA denied its New Drug Application for oliceridine.

If you were negatively impacted by your investment in Trevena Inc securities between May 2, 2016 and October 8, 2018 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185